A Scoping Review of the Use of Pioglitazone in the Treatment of Temporo-Mandibular Joint Arthritis

Thiazolidinediones (TZDs) are a group of diabetes medications currently being investigated for anti-arthritis effectiveness, one of which is pioglitazone. The purpose of this scoping review is to evaluate the potential use of pioglitazone in the treatment of temporomandibular joint (TMJ) arthritis. The criteria of eligibility were studies with the diagnosis of arthritis and pioglitazone treatment with a change in any inflammation index as an outcome. Of the 1169 records initially identified following the selection process, two animal studies and four clinical studies were included in the review. Improvements from the baseline were observed in each treatment group for each inflammation indicator. The results of the animal studies on the temporomandibular joints and on patients with rheumatoid and psoriatic arthritis indicate that the drug in question may have potential to treat arthritis, including within the temporomandibular joint.

[1]  P. Cascone,et al.  Temporomandibular Joint Surgery: Open Discopexy and "Functional Arthroplasty". , 2022, Atlas of the oral and maxillofacial surgery clinics of North America.

[2]  D. Chlubek,et al.  Repeated Intra-Articular Administration of Platelet-Rich Plasma (PRP) in Temporomandibular Disorders: A Clinical Case Series , 2022, Journal of clinical medicine.

[3]  Hua Chen,et al.  Efficacy and Safety of Curcumin and Curcuma longa Extract in the Treatment of Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trial , 2022, Frontiers in Immunology.

[4]  Qilong Wang,et al.  The Relationship Between Porphyromonas Gingivalis and Rheumatoid Arthritis: A Meta-Analysis , 2022, Frontiers in cellular and infection microbiology.

[5]  D. Chlubek,et al.  Treatment of Mandibular Hypomobility by Injections into the Temporomandibular Joints: A Systematic Review of the Substances Used , 2022, Journal of clinical medicine.

[6]  Y. Boirie,et al.  A Meta-Analysis of the Impact of Nutritional Supplementation on Osteoarthritis Symptoms , 2022, Nutrients.

[7]  D. Chlubek,et al.  The Administration of Hyaluronic Acid into the Temporomandibular Joints’ Cavities Increases the Mandible’s Mobility: A Systematic Review and Meta-Analysis , 2022, Journal of clinical medicine.

[8]  R. Gan,et al.  Natural products modulating interleukins and other inflammatory mediators in tumor-bearing animals: A systematic review. , 2022, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[9]  L. Argueta-Figueroa,et al.  Nonpharmacological Interventions for Pain in Patients with Temporomandibular Joint Disorders: A Systematic Review , 2022, European journal of dentistry.

[10]  M. Dougados,et al.  2022 French Society for Rheumatology (SFR) recommendations on the everyday management of patients with spondyloarthritis, including psoriatic arthritis. , 2022, Joint bone spine.

[11]  Yue He,et al.  Top 100 Cited Articles on Osteoarthritis from 1990 to 2020 , 2021, Rheumatology and immunology research.

[12]  A. Caprioglio,et al.  Three-dimensional volumetric evaluation of the different mandibular segments using CBCT in patients affected by juvenile idiopathic arthritis: a cross-sectional study , 2021, Progress in Orthodontics.

[13]  Aleksandra Nitecka-Buchta,et al.  Intramuscular Injections and Dry Needling within Masticatory Muscles in Management of Myofascial Pain. Systematic Review of Clinical Trials , 2021, International journal of environmental research and public health.

[14]  Arvind Muthukrishnan,et al.  Clinical Practice Guidelines for the Management of Temporomandibular Joint Disorders – A Review , 2021, Journal of Evolution of Medical and Dental Sciences.

[15]  J. Espín,et al.  Targeting Mammalian 5-Lipoxygenase by Dietary Phenolics as an Anti-Inflammatory Mechanism: A Systematic Review , 2021, International journal of molecular sciences.

[16]  B. Sokołowska,et al.  Temporomandibular joint disorders in patients with rheumatoid arthritis , 2021, Reumatologia.

[17]  E. Pawlowska,et al.  Mechanisms of Action and Efficacy of Hyaluronic Acid, Corticosteroids and Platelet-Rich Plasma in the Treatment of Temporomandibular Joint Osteoarthritis—A Systematic Review , 2021, International journal of molecular sciences.

[18]  I. Moppett,et al.  Preoperative inflammatory mediators and postoperative delirium: systematic review and meta-analysis. , 2021, British journal of anaesthesia.

[19]  D. Chlubek,et al.  Variants and Modifications of the Retroauricular Approach Using in Temporomandibular Joint Surgery: A Systematic Review , 2021, Journal of clinical medicine.

[20]  Y. Chai,et al.  Effectiveness of resistance exercises in the treatment of rheumatoid arthritis , 2021, Medicine.

[21]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.

[22]  M. Troulis,et al.  Is there a difference in treatment effect of different intra-articular drugs for temporomandibular joint osteoarthritis? A systematic review of randomized controlled trials. , 2021, International journal of oral and maxillofacial surgery.

[23]  L. Esposito,et al.  Safety and Effects of the Rapid Maxillary Expander on Temporomandibular Joint in Subjects Affected by Juvenile Idiopathic Arthritis: A Retrospective Study , 2021, Children.

[24]  W. Lu,et al.  Role of peroxisome proliferator-activated receptors in osteoarthritis (Review). , 2020, Molecular medicine reports.

[25]  S. Hasan,et al.  Low-level laser therapy in temporomandibular joint disorders: a systematic review , 2021, Journal of medicine and life.

[26]  P. Schrauwen,et al.  Type 2 diabetes subgroups and potential medication strategies in relation to effects on insulin resistance and beta-cell function: A step toward personalised diabetes treatment? , 2020, Molecular metabolism.

[27]  Kathryn M. Hurren,et al.  Are thiazolidinediones a preferred drug treatment for type 2 diabetes? , 2020, Expert opinion on pharmacotherapy.

[28]  M. Ennis,et al.  Histamine receptors and COVID-19 , 2020, Inflammation research : official journal of the European Histamine Research Society ... [et al.].

[29]  M. Dougados,et al.  Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement , 2020, Annals of the Rheumatic Diseases.

[30]  M. Borysewicz-Lewicka,et al.  Early diagnosis of temporomandibular joint arthritis in children with juvenile idiopathic arthritis. A systematic review. , 2020, European journal of paediatric dentistry.

[31]  S. Bonassi,et al.  Association of inflammatory mediators with frailty status in older adults: results from a systematic review and meta-analysis , 2020, GeroScience.

[32]  F. Bénard,et al.  A Systematic Review of Molecular Imaging Agents Targeting Bradykinin B1 and B2 Receptors , 2020, Pharmaceuticals.

[33]  Q. Lu,et al.  The roles of PPARγ and its agonists in autoimmune diseases: A comprehensive review , 2020, Journal of Autoimmunity.

[34]  M. Walshe,et al.  Modified Diet Use in Adults with Temporomandibular Disorders related to Rheumatoid Arthritis: A Systematic Review , 2020, Mediterranean journal of rheumatology.

[35]  D. Chlubek,et al.  Short-Term Effects of Intra-Articular Hyaluronic Acid Administration in Patients with Temporomandibular Joint Disorders , 2020, Journal of clinical medicine.

[36]  A. Iagnocco,et al.  Differential Diagnosis of Inflammatory Arthropathies by Musculoskeletal Ultrasonography: A Systematic Literature Review , 2020, Frontiers in Medicine.

[37]  B. Koes,et al.  Non-steroidal anti-inflammatory drugs for acute low back pain. , 2020, The Cochrane database of systematic reviews.

[38]  M. Wiese,et al.  Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis , 2020, Expert opinion on investigational drugs.

[39]  T. Kawaguchi,et al.  Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis , 2020, International journal of molecular sciences.

[40]  J. Erickson,et al.  Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1) , 2020, Rheumatology.

[41]  J. R. Neto,et al.  Pharmacological strategies for insulin sensitivity: thiazolidinediones and metformin. , 2020, Current pharmaceutical design.

[42]  H. Lebovitz Thiazolidinediones: the Forgotten Diabetes Medications , 2019, Current Diabetes Reports.

[43]  Xiaobo Zhu,et al.  PPARγ preservation via promoter demethylation alleviates osteoarthritis in mice , 2019, Annals of the rheumatic diseases.

[44]  W. Ahsan The Journey of Thiazolidinediones as Modulators of PPARs for the Management of Diabetes: A Current Perspective. , 2019, Current pharmaceutical design.

[45]  M. Si,et al.  PPAR-γ agonist pioglitazone protects against IL-17 induced intervertebral disc inflammation and degeneration via suppression of NF-κB signaling pathway. , 2019, International immunopharmacology.

[46]  N. Sheibani,et al.  The impact of water molecules on binding affinity of the anti-diabetic thiazolidinediones for catalase: Kinetic and mechanistic approaches. , 2019, Archives of biochemistry and biophysics.

[47]  R. Christensen,et al.  Smoking cessation intervention for reducing disease activity in chronic autoimmune inflammatory joint diseases. , 2018, The Cochrane database of systematic reviews.

[48]  J. McGowan,et al.  PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation , 2018, Annals of Internal Medicine.

[49]  R. Xavier,et al.  Prevalence of rheumatoid cachexia in rheumatoid arthritis: a systematic review and meta‐analysis , 2018, Journal of cachexia, sarcopenia and muscle.

[50]  G. De Sarro,et al.  Indole and 2,4-Thiazolidinedione conjugates as potential anticancer modulators , 2018, PeerJ.

[51]  L. Serra-Majem,et al.  Osteoarthritis and the Mediterranean Diet: A Systematic Review , 2018, Nutrients.

[52]  Manna Zhang,et al.  Pioglitazone Use and Risk of Bladder Cancer: an In Vitro Study , 2018, International journal of medical sciences.

[53]  N. Horita,et al.  Diagnostic test accuracy of ultrasound for synovitis in rheumatoid arthritis: systematic review and meta-analysis , 2018, Rheumatology.

[54]  P. Bundhun,et al.  Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone in the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials , 2017, BMC Pharmacology and Toxicology.

[55]  I. Banerjee,et al.  Effects of co-treatment with pioglitazone and methotrexate on experimentally induced rheumatoid arthritis in Wistar albino rats , 2017, Indian journal of pharmacology.

[56]  A. Sidebottom,et al.  Management of the temporomandibular joint in inflammatory arthritis: Involvement of surgical procedures. , 2017, European journal of rheumatology.

[57]  Chi Ma,et al.  Pioglitazone inhibits advanced glycation end product-induced matrix metalloproteinases and apoptosis by suppressing the activation of MAPK and NF-κB , 2016, Apoptosis.

[58]  M. Masiuk,et al.  Effect of methylprednisolone, hyaluronic acid and pioglitazone on histological remodeling of temporomandibular joint cartilage in rabbits affected by drug-induced osteoarthritis. , 2016, Postepy higieny i medycyny doswiadczalnej.

[59]  Y. Xia,et al.  Establishment of a rabbit model to study the influence of advanced glycation end products accumulation on osteoarthritis and the protective effect of pioglitazone. , 2016, Osteoarthritis and cartilage.

[60]  M. Erić,et al.  World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2016): Poster Abstracts , 2016, Osteoporosis International.

[61]  S. Gupta,et al.  Pioglitazone and the risk of bladder cancer: An Indian retrospective cohort study , 2015, Indian journal of endocrinology and metabolism.

[62]  I. Dicembrini,et al.  Drugs for type 2 diabetes: role in the regulation of bone metabolism. , 2015, Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases.

[63]  K. Tsai,et al.  PPARγ is involved in the hyperglycemia‐induced inflammatory responses and collagen degradation in human chondrocytes and diabetic mouse cartilages , 2015, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[64]  V. Chapman,et al.  Characterisation of Pain Responses in the High Fat Diet/Streptozotocin Model of Diabetes and the Analgesic Effects of Antidiabetic Treatments , 2015, Journal of diabetes research.

[65]  Ying Zhang,et al.  Pioglitazone Inhibits Advanced Glycation End Product-Induced TNF-E and MMP-13 Expression via the Antagonism of NF-TB Activation in Chondrocytes , 2014, Pharmacology.

[66]  M. A. Mohamed,et al.  Effect of pentoxifylline and pioglitazone on rheumatoid arthritis induced experimentally in rats , 2014 .

[67]  A. Shintani,et al.  Reversing Vascular Dysfunction in Rheumatoid Arthritis: Improved Augmentation Index but Not Endothelial Function With Peroxisome Proliferator–Activated Receptor γ Agonist Therapy , 2014, Arthritis & Rheumatology.

[68]  D. Jiang,et al.  PPAR-γ agonist pioglitazone affects rat gouty arthritis by regulating cytokines. , 2014, Genetics and molecular research : GMR.

[69]  K. Al-shamma,et al.  Evaluation of the Clinical use of Metformin or Pioglitazone in Combination with Meloxicam in Patients with Knee Osteoarthritis; using Knee Injury and Osteoarthritis outcome Score , 2014 .

[70]  R. Brook,et al.  The Peroxisome Proliferator Activated Receptor‐γ Pioglitazone Improves Vascular Function and Decreases Disease Activity in Patients With Rheumatoid Arthritis , 2013, Journal of the American Heart Association.

[71]  D. Chappard,et al.  The peroxisome proliferator-activated receptor γ agonist pioglitazone preserves bone microarchitecture in experimental arthritis by reducing the interleukin-17-dependent osteoclastogenic pathway. , 2013, Arthritis and rheumatism.

[72]  A. Consoli,et al.  Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus? , 2013, Diabetes, obesity & metabolism.

[73]  S. Suke,et al.  Anti-arthritic and anti-inflammatory activity of combined pioglitazone and prednisolone on adjuvant-induced arthritis. , 2013, European journal of pharmacology.

[74]  C. Stein,et al.  Peroxisome proliferator-activated receptor γ agonist effect on rheumatoid arthritis: a randomized controlled trial , 2013, Arthritis Research & Therapy.

[75]  Thomas M. MacDonald,et al.  Pioglitazone and bladder cancer: a propensity score matched cohort study. , 2013, British journal of clinical pharmacology.

[76]  David Samson,et al.  Chapter 2: Medical Tests Guidance (2) Developing the Topic and Structuring Systematic Reviews of Medical Tests: Utility of PICOTS, Analytic Frameworks, Decision Trees, and Other Frameworks , 2012, Journal of general internal medicine.

[77]  A. Ferrara,et al.  Cohort Study of Pioglitazone and Cancer Incidence in Patients With Diabetes , 2011, Diabetes Care.

[78]  J. Pelletier,et al.  Peroxisome proliferator-activated receptor gamma in osteoarthritis , 2011, Modern rheumatology.

[79]  V. Boshra,et al.  Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders Effect of Peroxisome Proliferator-activated Receptor Gamma Agonist (pioglitazone) and Methotrexate on Disease Activity in Rheumatoid Arthritis (experimental and Clinical Study) , 2022 .

[80]  Chia-Ron Yang,et al.  THIAZOLIDINEDIONES INHIBIT TNF-&agr;-MEDIATED OSTEOCLAST DIFFERENTIATION OF RAW264.7 MACROPHAGES AND MOUSE BONE MARROW CELLS THROUGH DOWNREGULATION OF NFATc1 , 2010, Shock.

[81]  S. Mudaliar,et al.  Pioglitazone: side effect and safety profile , 2010, Expert opinion on drug safety.

[82]  K. Menon,et al.  Thiazolidinediones decrease vascular endothelial growth factor (VEGF) production by human luteinized granulosa cells in vitro. , 2007, Fertility and sterility.

[83]  S. Theocharis,et al.  Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands as potential therapeutic agents to treat arthritis. , 2009, Pharmacological research.

[84]  Y. Moriwaki,et al.  Effects of benzbromarone and allopurinol on adiponectin in vivo and in vitro. , 2009, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[85]  S. Sébillaud,et al.  Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis , 2008, Arthritis research & therapy.

[86]  D. Puleo,et al.  Immune System and Inflammation , 2003, Indian journal of pharmacology.

[87]  J. Pelletier,et al.  The peroxisome proliferator-activated receptor gamma agonist pioglitazone reduces the development of cartilage lesions in an experimental dog model of osteoarthritis: in vivo protective effects mediated through the inhibition of key signaling and catabolic pathways. , 2007, Arthritis and rheumatism.

[88]  P. Komesaroff,et al.  The anti-atherogenic effects of thiazolidinediones. , 2007, Current diabetes reviews.

[89]  S. Edelson,et al.  Effect of pioglitazone treatment on behavioral symptoms in autistic children , 2007, Journal of Neuroinflammation.

[90]  J. Hardies,et al.  A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.

[91]  A. Krentz,et al.  Type 2 diabetes, psoriasis and thiazolidinediones , 2006, International journal of clinical practice.

[92]  D. Hornung,et al.  Implication for Thiazolidinediones (TZDs) as Novel Potential Anti- Inflammatory Drugs , 2005 .

[93]  J. Pelletier,et al.  Pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, reduces the progression of experimental osteoarthritis in guinea pigs. , 2005, Arthritis and rheumatism.

[94]  T. Vogt,et al.  Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study. , 2005, Rheumatology.

[95]  G. Wells,et al.  Celecoxib for rheumatoid arthritis. , 2017, The Cochrane database of systematic reviews.

[96]  Susan M. Kilroy,et al.  PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. , 2002, The Journal of clinical investigation.

[97]  T. Mayumi,et al.  PPAR gamma ligands inhibit nitrotyrosine formation and inflammatory mediator expressions in adjuvant-induced rheumatoid arthritis mice. , 2002, European journal of pharmacology.

[98]  C. Day Thiazolidinediones: a new class of antidiabetic drugs , 1999, Diabetic medicine : a journal of the British Diabetic Association.